Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 122 of the 123 references it cites were found in a registry or an index.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Abstract

Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of response. Response criteria in multiple myeloma were developed to use serum and urine assessment of monoclonal proteins and bone marrow assessment (which is relatively insensitive). Given the high rates of complete response seen in patients with multiple myeloma with new treatment approaches, new response categories need to be defined that can identify responses that are deeper than those conventionally defined as complete response. Recent attempts have focused on the identification of residual tumour cells in the bone marrow using flow cytometry or gene sequencing. Furthermore, sensitive imaging techniques can be used to detect the presence of residual disease outside of the bone marrow. Combining these new methods, the International Myeloma Working Group has defined new response categories of minimal residual disease negativity, with or without imaging-based absence of extramedullary disease, to allow uniform reporting within and outside clinical trials. In this Review, we clarify several aspects of disease response assessment, along with endpoints for clinical trials, and highlight future directions for disease response assessments.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(16)30206-6

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 123 references

Research works printed but not linked: 1

  1. Ghimire, 2013, Incidence and survival outcomes of extramedullary myeloma, Blood, 122, 3141

Cited by

See all 3,061

Metadata

Authors
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., Dimopoulos, M., Kastritis, E., Boccadoro, M., Orlowski, R., Goldschmidt, H., Spencer, A., Hou, J., Chng, W. J., Usmani, S. Z., Zamagni, E., Shimizu, K., Jagannath, S., Johnsen, H. E., Terpos, E., Reiman, A., Kyle, R. A., Sonneveld, P., Richardson, P. G., McCarthy, P., Ludwig, H., Chen, W., Cavo, M., Harousseau, J.-L., Lentzsch, S., Hillengass, J., Palumbo, A., Orfao, A., Rajkumar, S. V., Miguel, J. S., & Avet-Loiseau, H.
Affiliations
  • Mayo Clinic (US)
  • Clinica Universidad de Navarra (ES)
  • Dana-Farber Cancer Institute (US)
  • Cedars-Sinai Medical Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Emory University (US)
  • Hospital Clínic de Barcelona (ES)
  • National and Kapodistrian University of Athens (GR)
  • Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
  • The University of Texas MD Anderson Cancer Center (US)
  • Heidelberg University (DE)
  • The Alfred Hospital (AU)
  • Shanghai Changzheng Hospital (CN)
  • National University Health System (SG)
  • Carolinas Healthcare System (US)
  • University of Bologna (IT)
  • Tokai Central Hospital (JP)
  • Tisch Cancer Institute (US)
  • Aalborg University Hospital (DK)
  • Erasmus MC (NL)
  • Roswell Park Comprehensive Cancer Center (US)
  • Wilhelminen Hospital (AT)
  • Columbia University (US)
Corresponding author
Kumar, Shaji
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2016-08
Volume
17
Issue
8
Pages
e328-e346
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2486629951
Cited by
3,061
References
123
Citations by year
2026: 311 · 2025: 404 · 2024: 417 · 2023: 388 · 2022: 324 · 2021: 357 · 2020: 319 · 2019: 210 · 2018: 165 · 2017: 137 · 2016: 17
FWCI
167.82
Type
journal article
Language
en
Update notices
erratum (2016-09-01)
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
multiple myeloma, treatment response assessment, minimal residual disease, response criteria, complete response, monoclonal protein, extramedullary disease, clinical trial endpoints, flow cytometry, gene sequencing
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma, Practice Guidelines as Topic, Neoplasm, Residual, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. https://app.cochat.ai/papers/10.1016/s1470-2045(16)30206-6
The paper
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., Dimopoulos, M., Kastritis, E., Boccadoro, M., Orlowski, R., Goldschmidt, H., Spencer, A., Hou, J., Chng, W. J., Usmani, S. Z., . . . Avet-Loiseau, H. (2016). International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(16)30206-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.